STAT2 Antikörper (pTyr690)

Produktnummer ABIN349594

Hersteller Produkt- Nr.: 600-401-a93

Produktdetails anti-STAT2 Antikörper

Target: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Bindungsspezifität: pTyr690

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser STAT2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Hersteller Produkt- Nr.: 600-401-a93

Hersteller: Rockland

Verwendungszweck: STAT2 phospho Y690 Antibody

Kreuzreaktivität (Details): This affinity purified antibody is directed against human STAT2 pY690 protein.

Produktmerkmale: Synonyms: rabbit anti-STAT2 pY690 antibody, phosphorylated STAT2 antibody, STAT-2, STAT 2, Signal transducer and activator of transcription 2, p113

Aufreinigung: The product was affinity purified from monospecific antiserum by immunoaffinity chromatography.

Sterilität: Sterile filtered

Immunogen:

Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to a C-terminus region near phospho Tyrosine 690 of human STAT2 protein.

Immunogen Type: Conjugated Peptide

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

Immunohistochemistry Dilution: 1:100

Application Note: This affinity purified antibody has been tested for use in ELISA, western blotting, and IHC.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 113 kDa in size corresponding to STAT2 pY690 protein by western blotting in the appropriate cell lysate or extract.

Western Blot Dilution: 1:500 - 1:1000

ELISA Dilution: 1:85,000

Other: User Optimized

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.15 mg/mL

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: None

Preservative: 0.01 % (w/v) Sodium Azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Haltbarkeit: 12 months

Referenzen für anti-STAT2 Antikörper (ABIN349594)

Yamauchi, Takeuchi, Chihara, Honjoh, Kato, Yoshiki, Hotta, Sada: "STAT1 is essential for the inhibition of hepatitis C virus replication by interferon-λ but not by interferon-α." in: Scientific reports, Vol. 6, pp. 38336, (2018) (PubMed).

Details zu STAT2

Target: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Andere Bezeichnung: STAT2 (STAT2 Produkte)

Hintergrund: Background: This antibody is designed, produced, and validated as part of a collaboration with the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. STAT2 is a member of the STAT family of transcription factors.  Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex.  This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription.  Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation.  IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment.  Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha.  Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer.  From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.

Gen-ID: 6773

NCBI Accession: NP_005410

UniProt: P52630

Pathways: JAK-STAT Signalweg, Hepatitis C, CXCR4-mediated Signaling Events